Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol

Background: The oral dual endothelin receptor antagonist bosentan improves exercise capacity and delays clinical worsening in patients with pulmonary arterial hypertension, but its use could delay starting intravenous epoprostenol, a life saving treatment. Methods: Survival in patients with function...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Sitbon, O, McLaughlin, V, Badesch, D, Barst, R, Black, C, Galie, N, Humbert, M, Rainisio, M, Rubin, L, Simonneau, G
Format: Artigo
Jezik:Inglês
Izdano: BMJ Group 2005
Teme:
Pulmonary Hypertension
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1747276/
https://ncbi.nlm.nih.gov/pubmed/16055621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thx.2005.040618
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items